Interim Report April – December 2025

EQL Pharma delivered a record third quarter with sales of SEK 118.9m (+29% y/y) and operating profit (EBIT) of SEK 19.5m (+32% y/y), producing an EBITDA margin of 21% and a gross margin of 42%; cash totaled SEK 72.7m with SEK 34.0m of unused working capital facilities. Management launched one product (raising launched portfolio to 47), added six to the pipeline (now 50), and is advancing launches/approvals across BeNeLux, Germany, France and GCC, but ongoing stockouts and some Covid-test scrapping temper near-term targets and leave full-year sales growth guidance at about 15%.

Analysis

Market structure: EQL’s Q3 (sales +29% y/y to SEK 118.9m; EBITDA margin 21%) reinforces winner status for niche Nordic generics specialists that can scale into adjacent EU markets. Winning products: Memprex/Mellozzan and newly launched SKU pipeline (47 launched, 50 in pipeline) increase pricing/market-share defensibility in low-competition niches; larger commodity generics (TEVA, Sandoz/Novartis divisions) face continued margin pressure from scale competition. Inventory normalization (Q4) will convert backlog into near-term revenue; scrap of COVID tests drags ~3–4pp off FY growth, so real organic demand is stronger than headline FY +15% guidance.

Risk assessment: Key tail risks are regulatory rejection (BeNeLux RUP or German/French launches) and supplier failure/transport shocks (Red Sea corridors) that could reintroduce >10% quarterly sales volatility. Immediate (days): market reaction to this report and liquidity; short-term (3–9 months): BeNeLux RUP timeline (6–9 months) and German pilot (spring 2026) are binary catalysts; long-term (3–5 years): execution vs. target EBITDA 25% hinges on ERP rollout and supplier redundancy. Hidden dependencies include single-source CMOs and receivables concentration; threshold watch: cash >SEK50m and net debt/EBITDA <3 are sanity checks.

Trade implications: Tactical: small-cap long exposure to EQL (Nasdaq Stockholm: EQL) with 12-month upside tied to German/BeNeLux launches; pair trade long EQL vs short TEVA (NASDAQ: TEVA) to neutralize sector beta. Options: buy 9–12 month call spread on EQL (ATM to +20%) financed by selling +40% OTM calls or, if illiquid, buy equity + purchase 6-month 12% OTM puts as protection. Rotate 1–3% portfolio weight into niche-generics/Europe small-caps and trim large-cap commodity generics.

Contrarian angles: Market may underprice the optionality of repeat-use approvals and German pilot; a successful RUP + Germany launch could drive >30% rerating within 9–12 months given current market cap implied multiples. Conversely, consensus underestimates ERP/implementation risk — a botched ERP or supplier insolvency could remove >15% of next-quarter revenue. Action triggers: add on margin stability (>20% EBITDA) and cash >SEK60m; cut on missed RUP timelines or inventory-driven sequential sales decline >10%.

Key Decisions for Investors

• Initiate a 2–3% long position in EQL Pharma (Nasdaq Stockholm: EQL) within 1–4 weeks; target +30–40% upside over 12 months if German pilot (spring 2026) and BeNeLux RUP (6–9 months) progress as guided. Place a hard stop-loss at -15% from entry or if next quarter EBITDA margin falls below 18%.
• Establish a dollar-neutral pair: long EQL (2% portfolio) vs short TEVA (NASDAQ: TEVA) (2% notional) for 6–12 months to capture relative outperformance from niche premium vs commodity generics headwinds; rebalance if TEVA spreads outperform by >10%.
• If options/liquidity permits, buy a 9–12 month call spread on EQL (buy ATM, sell +20% strike) sized to 1% portfolio risk, or alternatively buy EQL equity hedged with 6-month 12% OTM puts to cap downside. Close or roll if share gains >40% or if put cost >3% of position value.
• Reduce 2–4% exposure to large commodity generic manufacturers (e.g., TEVA, large Sandoz-exposed names) and reallocate into European niche-generics and specialty-distributors; increase cash reserve to cover supplier/disruption events until inventory days decline by at least 20% quarter-over-quarter.